TrialPath

Find a study

Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.

Match me to a study

10 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

10 studies on the map

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) — National Institutes of Health Clinical Center, BethesdaA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight — Arizona Clinical Trials, ChandlerTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation — Cleveland Clinic, ClevelandGlycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes — University Health - Texas Diabetic Institute, San AntonioMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamReal-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine — University of Miami, Miller School of Medicine, MiamiMAINTAIN (Mucosal AblatIoN Therapy After INcretins) — True You Weight Loss, CaryLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaEffect of Tirzepatide on Markers of MASLD in Patients With Obesity — University of New Mexico Health Sciences Center, Albuquerque